Erratum: The effects of strontium ranelate in Asian women with postmenopausal osteoporosis (Calcif Tissue Int (2008) 83:5 (308-314) DOI: 10.1007/s00223-008-9180-z);The effects of strontium ranelate in Asian women with postmenopausal osteoporosis

Calcified Tissue International

Volumn 83, Issue 5, 2008, Pages 308-314

  Hwang, J S ^a   Chen, J F ^a   Yang, T S ^b   Wu, D J ^c   Tsai, K S ^d   Ho, C ^a   Wu, C H ^c   Su, S L ^e   Wang, C J ^a   Tu, S T ^e  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

Bone mineral density; Osteoporosis; Strontium ranelate

Indexed keywords

ALKALINE PHOSPHATASE; PLACEBO; STRONTIUM RANELATE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; ASIAN; BACKACHE; BEDTIME DOSAGE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; FEMUR NECK; GASTROINTESTINAL DISEASE; HUMAN; HYPERPHOSPHATEMIA; HYPERPHOSPHATURIA; INSOMNIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MUSCLE CRAMP; NUTRITIONAL DISORDER; PATIENT SATISFACTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TAIWAN; THIRST; TREATMENT DURATION; URINARY TRACT DISEASE;

EID: 58549102898     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-009-9233-y     Document Type: Erratum

References (31)

1. SR Cummings LJ Melton 2002 Epidemiology and outcomes of osteoporotic fractures Lancet 359 1761 1767
2. LJ Melton III 1995 How many women have osteoporosis now? J Bone Miner Res 10 175 177
3. KS Tsai TY Tai 1997 Epidemiology of osteoporosis in Taiwan Osteoporos Int 7 Suppl 3 S96 S98
4. TS Yang YR Chen YJ Chen CY Chang HT Ng 2004 Osteoporosis: prevalence in Taiwanese women Osteoporos Int 15 345 347
5. C Cooper 1997 The crippling consequences of fractures and their impact on quality of life Am J Med 103 12S 19S
6. JR Center TV Nguyen D Schneider PN Sambrook JA Eisman 1999 Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 878 882
7. DM Black SR Cummings DB Karpf JA Cauley DE Thompson MC Nevitt DC Bauer HK Genant WL Haskell R Marcus SM Ott JC Torner SA Quandt TF Reiss KE Ensrud 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Fracture Intervention Trial Research Group. Lancet 348 1535 1541
8. ST Harris NB Watts HK Genant CD McKeever T Hangartner M Keller CH Chesnut III J Brown EF Eriksen MS Hoseyni DW Axelrod PD Miller 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352
9. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441
10. R Eastell 1998 Treatment of postmenopausal osteoporosis N Engl J Med 338 736 746
11. CH Chesnut III S Silverman K Andriano H Genant A Gimona S Harris D Kiel M LeBoff M Maricic P Miller C Moniz M Peacock P Richardson N Watts D Baylink 2000 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study PROOF Study Group. Am J Med 109 267 276
12. A Cranney G Guyatt L Griffith G Wells P Tugwell C Rosen Osteoporosis Methodology Group, Osteoporosis Research Advisory Group 2002 Meta-analyses of therapies for postmenopausal osteoporosis IX: summary of meta-analyses of therapies for postmenopausal osteoporosis Endocr Rev 23 570 578
13. JS Hwang ST Tu TS Yang JF Chen CJ Wang KS Tsai 2006 Teriparatide vs calcitonin in the treatment of Asian postmenopausal women with established osteoporosis Osteoporos Int 17 373 378
14. ML Yen BL Yen MH Jang SH Hsu WC Cheng KS Tsai 2000 Effects of alendronate on osteopenic postmenopausal Chinese women Bone 27 681 685
15. N Burlet JY Reginster 2006 Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis Clin Orthop Relat Res 443 55 60
16. PJ Marie P Ammann G Boivin C Rey 2001 Mechanisms of action and therapeutic potential of strontium in bone Calcif Tissue Int 69 121 129
17. JY Reginster E Seeman MC De Vernejoul S Adami J Compston C Phenekos JP Devogelaer MD Curiel A Sawicki S Goemaere OH Sorensen D Felsenberg PJ Meunier 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 2822
18. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh EM Lemmel S Pors-Nielsen R Rizzoli HK Genant JY Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468
19. HK Genant CY Wu KC van MC Nevitt 1993 Vertebral fracture assessment using a semiquantitative technique J Bone Miner Res 8 1137 1148
20. A Barbara P Delannoy BG Denis PJ Marie 2004 Normal matrix mineralization induced by strontium ranelate in MC3T3-E1 osteogenic cells Metabolism 53 532 537
21. E Canalis M Hott P Deloffre Y Tsouderos PJ Marie 1996 The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro Bone 18 517 523
22. R Baron Y Tsouderos 2002 In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation Eur J Pharmacol 450 11 17
23. N Takahashi T Sasaki Y Tsouderos T Suda 2003 S12911-2 inhibits osteoclastic bone resorption in vitro J Bone Miner Res 18 1082 1087
24. J Buehler P Chappuis JL Saffar Y Tsouderos A Vignery 2001 Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis) Bone 29 176 179
25. P Delannoy D Bazot PJ Marie 2002 Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice Metabolism 51 906 911
26. Ammann P, Shen V, Robin B, Mauras Y, Bonjour JP, Rizzoli R (2004) Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats [erratum appears in J Bone Miner Res 2005;20:548]. J Bone Miner Res 19:2012-2020
27. NS Pors 2004 The biological role of strontium Bone 35 583 588
28. PJ Meunier DO Slosman PD Delmas JL Sebert ML Brandi C Albanese R Lorenc S Pors-Nielsen MC De Vernejoul A Roces JY Reginster 2002 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial J Clin Endocrinol Metab 87 2060 2066
29. S Ortolani S Vai 2006 Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages Bone 38 Suppl 1 19 22
30. SP Nielsen D Slosman OH Sorensen B Basse-Cathalinat CP De CR Roux PJ Meunier 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry J Clin Densitom 2 371 379
31. GM Blake I Fogelman 2007 Effect of bone strontium on BMD measurements J Clin Densitom 10 34 38